Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
May 15, 2024 07:30 ET
|
Verrica Pharmaceuticals Inc.
Global pivotal Phase 3 clinical trial would be conducted jointly by Verrica and Torii Pharmaceutical; trial expected to begin in the 1st half of 2025 Amendment should benefit both parties from a cost...
Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results
May 13, 2024 07:30 ET
|
Verrica Pharmaceuticals Inc.
– Reports YCANTH® revenue of $3.2M for first quarter of 2024 – – Over 228 million lives now covered to date on commercial insurance, managed Medicaid, Tricare and Federal Employee plans – –...
Verrica Pharmaceuticals to Present at Upcoming Investor Conferences
May 09, 2024 07:30 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin...
Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024
May 08, 2024 07:30 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin...
Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
April 02, 2024 07:30 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
March 26, 2024 07:30 ET
|
Verrica Pharmaceuticals Inc.
NCE status provides a minimum of five years of regulatory exclusivity The Company’s U.S. patents and pending patent applications related to YCANTH™ are projected to expire between 2034 and 2041,...
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
February 29, 2024 07:30 ET
|
Verrica Pharmaceuticals Inc.
– Reports YCANTH™ revenue of $1.9M for fourth quarter and $4.7M for full year 2023 – – Over 200 million lives now covered on commercial insurance and managed Medicaid plans – – Conference Call...
Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference
February 27, 2024 07:30 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin...
Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024
February 22, 2024 07:30 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin...
Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition
February 05, 2024 07:30 ET
|
Verrica Pharmaceuticals Inc.
Lawsuit alleges false and misleading advertising and promotion of unapproved cantharidin-containing drugs by Dormer Laboratories in violation of federal and state law WEST CHESTER, Pa., Feb. 05,...